JPRN-UMIN000031730已完成未知
Effects of pyridoxamine for peritoneal injury in patients with peritoneal dialysis: Search of the effective end-point - PYDinPD-S
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •>Combined therapy with PD and hemodialysis >Severe liver disease >Previous severe adverse effect and all allergy >Participating other clinical stadies >Malignancy, or less than 3-years after treatment of the cancer >Less than 6-months from previous cardiovascular disease (myocaridial infarction and apoplexy) >More than 8 years PD, or having enca psulating peritoneal sclerosis. >Peripheral arterial disease (more than class 2 of Fontaine classification). >Uncontrolled hypertension (more than 180mmHg of systolic BP and 120mmHg of diastolic BP). >HbA1c >8.0%. >Severe anemia (Hb <9.0g/dl) >Using aminophylline, theophylline, cholinetheophylline, levodopa, pyridoxa l, pyridoxine, and other vitamin B6 agen ts within 4 weeks. >Expected pregnancy within 1 year. >Others judged to be excluded by doc tors.
研究者
相似试验
招募中
2 期
Pyridoxamine for menopausal disordermenopausal disorder with psychological symptomsJPRN-jRCTs031220256Terauchi Masakazu50
已完成
2 期
The efficacy and safety of pyridoxamine in patients with autism spectrum disorder; Exploratory physician-led Phase 2 trialAutism Spectrum DisorderJPRN-jRCT2021200001Kure Shigeo78
已完成
2 期
The efficacy and safety of pyridoxamine in patients with autism spectrum disorder; Exploratory physician-led Phase II trialAutism spectrum disorderJPRN-UMIN000035172Department of Pediatrics,Tohoku University Hospital72
已完成
2 期
The efficacy and safety of pyridoxamine in patients with autism spectrum disorder; Exploratory physician-led Phase 2 trialAutism Spectrum DisorderJPRN-jRCT2091220438Department of Pediatrics, Tohoku University Hospital79
招募中
不适用
The effect of pyridoxamine supplementation on microvascular function in type 2 diabetes: a double-blind randomized placebo-controlled cross-over trialNL-OMON56635niversiteit Maastricht40